Drug Profile
Sirolimus-eluting coronary stent - Lepu Medical Technology (Beijing)
Alternative Names: NeoVas BCS - Lepu Medical Technology; NeoVas bioresorbable coronary scaffold - Lepu Medical TechnologyLatest Information Update: 30 Dec 2021
Price :
$50
*
At a glance
- Originator Lepu Medical Technology (Beijing)
- Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
- Mechanism of Action Immunosuppressants; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Coronary artery disease
Most Recent Events
- 06 Aug 2021 Lepu Medical Technology plans a clinical trail for Coronary artery disease in September 2021 (NCT04995159)
- 26 Aug 2017 Efficacy data from a clinical trial in Coronary artery disease presented at the the ESC Congress 2017: Annual Congress of the European Society of Cardiology (ESC-2017)
- 26 Aug 2017 Lepu Medical Technology (Beijing) completes the clinical trial in Coronary artery disease in China